D. Buononato
24 Papers
4 Citations
D. Buononato is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 12 publications.
Chat about Author
Papers
The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers
Anna Balato,Alexander Zink,Graziella Babino,D. Buononato,Charlotte Kiani,Kilian Eyerich,Stefanie Ziehfreund,Emanuele Scala +7 more
TL;DR: In this article , a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in psoriasis (PSO) and atopic dermatitis (AD) was conducted.
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
D. Orsini,Piergiorgio Malagoli,Anna Balato,L. Bianchi,Pina Brianti,D. Buononato,M. Burlando,G. Caldarola,Anna Campanati,Elena Campione,C. Carrera,Andrea Carugno,F. Cusano,Paolo Dapavo,Annunziata Dattola,P. De Simone,V. Dini,Maria Esposito,Maria Concetta Fargnoli,Francesca Gaiani,Luigi Gargiulo,Paolo Gisondi,Alessandro Giunta,L. Ibba,Claudia Lasagni,Francesco Loconsole,Vincenzo Maione,Edoardo Mortato,A. Marzano,Martina Maurelli,Matteo Megna,Santo Raffaele Mercuri,Alessandra Narcisi,Annamaria Offidani,G. Paolino,A. Parodi,G. Pellacani,L. Potestio,P. Quaglino,Antonio Giovanni Richetta,Francesca Romano,Paolo Sena,Marina Venturini,C. Assorgi,A. Costanzo +44 more
TL;DR: This 16-week real-world study evaluates bimekizumab's efficacy in treating moderate-to-severe plaque psoriasis with genital involvement, demonstrating significant improvements in sPGA-G and PASI scores, and enhanced quality of life in 65 adult patients.
9
A case of Hailey‐Hailey disease successfully treated with dupilumab
Gaetano Licata,D. Buononato,Giulia Calabrese,Alessio Gambardella,Giulia Briatico,Francesca Pagliuca,Giuseppe Argenziano +6 more
TL;DR: The case of Hailey-Hailey disease successfully treated with dupilumab is described, a chronic difficult-to-treat disease with negative impact on a patient’s quality of life because therapeutic options remain limited and not always effective.
8
Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
Eugenia Veronica Di Brizzi,D. Buononato,Pierfrancesco Benvenuto,Giuseppe Argenziano,Rocco De Pasquale,Carmen Fiorella,F. Giofrè,Maria Letizia Musumeci,Giovanni Palazzo,Leonardo Zichichi,Anna Balato +10 more
TL;DR: The effectiveness of tildrakizumab in daily clinical practice in patients with moderate-to-severe plaque psoriasis is confirmed, with a significant decrease at week 12 and even more at week 48 (P <0.001), and the effectiveness was confirmed also by DLQI assessment.
Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis
D. Buononato,Gaetano Licata,Alessio Gambardella,A. De Rosa,Giulia Calabrese,Giuseppe Argenziano +5 more
TL;DR: This is an open-access article distributed under the terms of the Creative Commons AttributionNonCommercial License (BY-NC-4.0), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
3